GAITHERSBURG, Md., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent” or the “Company”) today announced that it has entered into an agreement to resolve the previously disclosed securities class action litigation pending in the United States District Court for the District of Maryland (In re Emergent BioSolutions Inc. Security Litigation, No. 8:21-cv-00955-DLB). This lawsuit was originally filed in 2021. Under the terms of the proposed settlement, Emergent will pay $40 mil ...

GAITHERSBURG, Md., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a contract modification executing an option period by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), valued at $41.9 million, for drug substance engineering and scale-up process validation, long term stability, and commercial ...

New York, New York, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Oak Hill Advisors (“OHA”) served as Administrative Agent and sole lender of a $250 million term loan facility supporting Emergent BioSolutions Inc. (“Emergent”) (NYSE: EBS), a global company providing life-saving and life-extending products that address public health threats. The new debt financing will refinance Emergent’s existing credit facility, reaching a significant step in its multi-year plan to stabilize its financial profile. In connection wit ...

Emergent BioSolutions Inc. (EBS) announced that the FDA has approved its supplemental biologics license application (sBLA) seeking a label expansion for ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live) to include prevention of mpox disease in individuals who are at increased risk of the disease.Shares of the company were up in pre-market trading on Friday following the announcement of the news.ACAM2000 is currently approved by the FDA as a single dose for active immunization against smallpox disease in ...

For the second year, Emergent is teaming up with pro football legend, Emmitt Smith, to educate communities on opioid risks and how to be prepared with NARCAN® Nasal SprayIn recognition of International Overdose Awareness Day, Emergent is bolstering efforts to increase awareness and availability of naloxone to ensure everyone has the power to save a life GAITHERSBURG, Md., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced it is kicking off the second year of the Ready ...

Thursday, the FDA approved Emergent BioSolutions Inc.’s EBS supplemental Biologics License Application (sBLA) for the expansion of the indication for ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live) to include prevention of mpox disease in individuals determined to be at high risk for mpox infection.The approval is based on previously available human safety data and data from a well-controlled animal study in which the ACAM2000 vaccine was shown to be effective in protecting against mpox virus exposure ...

GAITHERSBURG, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expansion of the indication for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to include prevention of mpox disease in individuals determined to be at high risk for mpox infection. The approval is based on previously available human safety data and data from a well-cont ...

GAITHERSBURG, Md., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has completed the sale of its drug product facility in Baltimore-Camden to an affiliate of Bora Pharmaceuticals Co., Ltd. (“Bora”, TWSE: 6472). Emergent received approximately $30 million at closing, which is subject to customary post-closing adjustments. With the transaction closed, Bora has acquired the assets, equipment, and workforce associated with the 87,000 square foot Baltimore-Camden manuf ...

Active engagement with the World Health Organization, U.S. government and other global health leaders on critical efforts to prevent mpox disease transmission50,000 doses of ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) will be donated to Direct Relief for potential deployment across often difficult-to-reach locations, and as informed by local and regional health authorities GAITHERSBURG, Md., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced it is proactively working with ...

Diy13 Emergent BioSolutions Overview Emergent BioSolutions (NYSE:EBS) has faced challenging circumstances, yet it is strongly positioned as an important player in public health. Earlier this year, I explored the high-risk, high-reward potential of EBS and its strategic turnaround efforts. Since then, significant strides have been made with its flagship product, NARCAN, which is central to the fight against the opioid crisis. Additionally, ACAM2000’s potential expanded indication approval for monkeypox i ...